说的比较片面，复星营_老虎社区_美港股上老虎

敢死队
2019-06-07

说的比较片面，复星营收200多亿，销售费用占30%多，从占比来看在医药公司里不算大，步长制药销售费用占营收60%这才是不合理的。说到新药研发投入复星18年投入25亿仅次于恒瑞医药26亿，其实复星是很有抱负的，作者写文章都没看过年报，文章里研发投入15亿你是哪里看到的，年报里显示是25亿，被你一写就少了10个亿。

非常抱歉，此主贴已删除

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":902745845,"tweetId":"902745845","gmtCreate":1559874054087,"gmtModify":1704699239431,"author":{"id":82055585880249,"idStr":"82055585880249","authorId":82055585880249,"authorIdStr":"82055585880249","name":"敢死队","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n 说的比较片面，复星营收200多亿，销售费用占30%多，从占比来看在医药公司里不算大，步长制药销售费用占营收60%这才是不合理的。说到新药研发投入复星18年投入25亿仅次于恒瑞医药26亿，其实复星是很有抱负的，作者写文章都没看过年报，文章里研发投入15亿你是哪里看到的，年报里显示是25亿，被你一写就少了10个亿。</body></html>","htmlText":"<html><head></head><body>\n 说的比较片面，复星营收200多亿，销售费用占30%多，从占比来看在医药公司里不算大，步长制药销售费用占营收60%这才是不合理的。说到新药研发投入复星18年投入25亿仅次于恒瑞医药26亿，其实复星是很有抱负的，作者写文章都没看过年报，文章里研发投入15亿你是哪里看到的，年报里显示是25亿，被你一写就少了10个亿。</body></html>","text":"说的比较片面，复星营收200多亿，销售费用占30%多，从占比来看在医药公司里不算大，步长制药销售费用占营收60%这才是不合理的。说到新药研发投入复星18年投入25亿仅次于恒瑞医药26亿，其实复星是很有抱负的，作者写文章都没看过年报，文章里研发投入15亿你是哪里看到的，年报里显示是25亿，被你一写就少了10个亿。","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/902745845","repostId":1906617528,"repostType":2,"isVote":1,"tweetType":1,"viewCount":1602,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":280,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}